SPHRY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 10:56):

Stats
Today's Volume	950.00
Average Volume	1 861.00
Market Cap	35.02M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.07
ATR14	$0 (0.00%)

Starpharma Holdings Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Starpharma Holdings Financials

Annual	2023
Revenue:	$2.94M
Gross Profit:	$1.22M (41.60 %)
EPS:	$-0.0382

Q2	2024
Revenue:	$7.20M
Gross Profit:	$6.43M (89.30 %)
EPS:	$-0.00250

Q1	2024
Revenue:	$4.01M
Gross Profit:	$1.28M (31.91 %)
EPS:	$-0.00130

Q4	2023
Revenue:	$1.85M
Gross Profit:	$985 000 (53.16 %)
EPS:	$-0.0180

Financial Reports:

No articles found.

Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.